GlassScriptPhysician profile
Monique A Prince
NPI 1528349297
$6,901.69
in general payments reported to CMS, 2019-2025
36 companies · $3,406 in 2025
The $3,406 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $409 · 2023: $1,206 · 2024: $1,880 · 2025: $3,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,492.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,161.12 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $758.40 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $450.57 | 2024-2025 | Otezla, Repatha, Otezla |
| Gilead Sciences, INC. | $281.00 | 2024-2025 | Livdelzi, Epclusa, Descovy |
| Neurocrine Biosciences, INC. | $233.82 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $231.09 | 2024-2025 | Austedo Xr |
| Abiomed | $228.52 | 2025 | |
| Astellas Pharma US INC | $169.47 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $166.31 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $156.61 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $147.16 | 2022-2023 | Spravato, Xarelto |
| Axsome Therapeutics, INC. | $146.82 | 2025 | Auvelity |
| Medtronic, INC. | $146.44 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $137.31 | 2022-2023 | |
| Grifols USA, LLC | $125.00 | 2024 | Prolastin-C Liquid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124.70 | 2022-2025 | Trelegy Ellipta |
| Eisai INC. | $111.59 | 2025 | |
| Exact Sciences Corporation | $107.75 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biogen, INC. | $107.28 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.11 | 2023-2024 | |
| Dexcom, INC. | $85.23 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $85.09 | 2023-2025 | |
| Edwards Lifesciences Corporation | $80.84 | 2024-2025 | Sapien 3 Ultra Resilia |
| Atricure, INC. | $79.01 | 2023 | |
| Genzyme Corporation | $68.34 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.82 | 2023-2025 | Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $56.99 | 2023-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.26 | 2024-2025 | Xifaxan, Trulance |
| Alnylam Pharmaceuticals INC. | $47.25 | 2024 | Amvuttra |
| Scilex Pharmaceuticals INC. | $32.79 | 2022-2023 | Ztlido |
| Shield Therapeutics INC | $32.36 | 2023-2025 | Accrufer |
| Hikma Pharmaceuticals USA | $29.14 | 2023-2025 | Ryaltris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.54 | 2025 | Caplyta |
| Bioventus LLC | $26.71 | 2022 | |
| Ardelyx, INC. | $22.86 | 2024 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $20.39 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.